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Abstract
Purpose of Review Cardiac troponin (cTn) plays an essential
role for assessment of outcome in acute coronary syndrome
(ACS). However, the prognostic value of cTn is not absolute.
In this mini-review, we summarize the evidence on the utility
of established biomarkers of left-ventricular dysfunction, he-
modynamic stress, inflammation, and renal dysfunction for
risk prediction beyond cTn in ACS.
Recent Findings Only few biomarkers consistently demon-
strate additive prognostic value to cTn levels. The B-type
natriuretic peptides (NPs) and growth-differentiation factor-
15 (GDF-15) are most promising in this regard. However,
there are uncertainties regarding the role of these biomarkers
for guidance of treatment decisions, and their prognostic in-
crement to cTn levels measured with high-sensitivity assays is
largely unknown.
Summary The NPs and GDF-15 provide the strongest prog-
nostic increment to cTn levels in ACS. However, the role of
these biomarkers for clinical decision-making in contempo-
rary settings has still to be defined.
Keywords Acute coronary syndrome . Biomarkers . Risk
prediction
Introduction
Cardiac troponin (cTn) is released from cardiomyocytes
exposed to ischemia severe enough to cause irreversible
cell damage [1]. Measurement of cTn levels plays an
essential role in the management of patients with suspi-
cion of an acute coronary syndrome (ACS), and elevated
levels are a prerequisite for the diagnosis of myocardial
infarction (MI) [2]. In patients with symptoms of ACS,
elevated cTn levels indicate the presence of an unstable
coronary lesion and an increased risk of recurrent ische-
mic events. Higher cTn levels correlate with a larger MI
size [3, 4] and, accordingly, greater mortality risk. cTn
levels are for this reason used for both short- and long-
term risk assessment, and cTn elevation is a commonly
used clue for the selection of patients to beneficial ther-
apies, e.g., coronary revascularization or anticoagulant
treatment [5, 6].
However, the prognostic value of cTn is not absolute.
For example, high-risk patients with unstable angina
usually do not have cTn elevation, and in ST-segment
MI (STEMI), cTn levels may be affected by reperfusion
modalities. Moreover, cTn levels do not cover all
pathobiologic processes being relevant in ACS, e.g., left
ventricular (LV) dysfunction, hemodynamic stress, in-
flammation, or renal dysfunction (Fig. 1). This has gen-
erated interest in prognostic biomarkers that can be used
in ACS together with cTn for improvement of risk pre-
diction. The past decades have seen a constant prolifer-
ation of such candidate biomarkers. In this mini-review,
we aimed to summarize the evidence on this important
topic. In order to provide information that is useful to
the practicing clinician, we limit this review to
established biomarkers that are measurable using cur-
rently marketed assays.
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Biomarkers of LV-Dysfunction—the Natriuretic
Peptides
B-type natriuretic peptide (BNP) and its prohormone, N-
terminal proBNP (NT-proBNP), are released from atrial
and ventricular cardiomyocytes in response to myocardial
stretch caused by volume or pressure overload. The
physiologic actions of the natriuretic peptides (NPs) in-
clude natriuresis, vasodilatation, and inhibition of the ef-
fects of the renin-angiotensin-aldosterone system (RAAS)
and the sympathetic nervous system. This counterbal-
ances fluid retention and possibly prevents maladaptive
forms of LV hypertrophy and fibrosis [7].
NP levels rise rapidly after myocardial ischemia as this
often causes a transient increase in LV wall tension and myo-
cardial stretch. The increases in NP levels in ACS are propor-
tional to the size of the ischemic insult but also reflective of
LV dysfunction during and prior to the current episode of
ACS, important predictors of adverse outcome [8–13]. NP
levels gradually decline during the course of weeks after
ACS [14•]. In some patients, particularly those who eventual-
ly develop heart failure (HF), a second peak may occur after
some days, reflecting adverse LV remodeling [8].
The NPs are powerful predictors of mortality and HF in
ACS patients presenting with and without ST-segment eleva-
tion, independent of echocardiographic findings and cTn re-
sults [9–12, 15••, 16]. Whether this holds true even when cTn
is measured using high-sensitivity (hs)-assays is at present
uncertain. The NPs enhance the prognostic information ob-
tained from the GRACE score [17, 18••] and are, moreover,
useful predictors of functional LV recovery after ACS [13].
The association of the NPs with recurrent ischemic events in
contrast is usually weak or non-existent in adjusted analyses.
This seems surprising given the close relation of NP levels
with the severity of coronary artery disease [19]. However,
there is no causal link between NP levels and atherothrombo-
sis which might explain this specific risk pattern.
The optimal timing of NPmeasurement for risk assessment
is uncertain. Samples obtained late during the hospitalization
or during follow-up are preferable to those obtained very early
as they provide stronger associations with subsequent events
[8, 14•, 16, 20]. However, whether or not temporal changes in
NP levels might be associated with a change in prognosis is
not clear [14•, 16, 20].
Several studies have investigated whether NP levels might
identify patients with non-ST segment elevation ACS (NSTE-
ACS) having particular benefit from an early invasive man-
agement. Although results from individual studies have been
conflicting [9, 10], a recent meta-analysis including 8125 pa-
tients from five studies demonstrated a significant mortality
reduction by an early invasive strategy in patients with “high”
NP levels [21••]. The risk ratio was 0.74 (95% confidence
interval [CI] 0.59–0.86), mainly driven by results from the
FRISC-II study [10]. Regarding P2Y12 inhibitors, an analysis
from the PLATO trial evaluating patients with all types of
ACS failed to prove an interaction of NT-proBNP levels with
the effect of ticagrelor treatment. However, NT-proBNP levels
contributed to the information on the magnitude of the prog-
nostic benefit of this drug [22].
As NP levels reflect the degree of LV dysfunction, it is
conceivable to believe that they might be useful for guidance
of pharmacological treatment improving LV remodeling. This
has been investigated in a British study including 1725 ACS
patients. In this analysis, a prognostic benefit from RAAS
inhibitors emerged, however, only in patients with NT-
proBNP levels in the highest quartile [23]. In the AVANT
GARDE-TIMI 43 trial investigating 1101 ACS patients with
elevated NP levels, no benefit of an early initiation of RAAS
inhibition with valsartan, aliskiren, or their combination was
seen compared with placebo [24]. In a prospective analysis
of the MERLIN-TIMI 36 trial investigating 4543 NSTE-
ACS patients, ranolazine, a drug with anti-ischemic ef-
fects, reduced the risk of adverse events in patients with
BNP >80 ng/L but not in those with lower levels. In con-
trast to the hypothesis that ranolazine may have a specific
effect on LV wall stress, it did not reduce BNP levels over
time in that study [25].
Biomarkers of Hemodynamic Stress—Copeptin
Copeptin is the c-terminal part of the prohormone of arginine-
vasopressin and is released from the neurohypophysis in situ-
ations associated with endogenous stress [26]. Copeptin levels
rise rapidly in multiple acute disorders including MI.
However, copeptin is not cardiospecific. Besides MI, elevated
Fig. 1 Pathobiologic mechanisms in acute coronary syndrome and
associated biomarkers. ACS acute coronary syndrome, LV left-
ventricular, BNP B-type natriuretic peptide, NT-proBNP N-terminal pro
B-type natriuretic peptide, CRP C-reactive protein, GDF-15 growth
differentiation factor-15, eGFR estimated glomerular filtration rate
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levels can also be found in other cardiac diseases, e.g., myocar-
ditis or HF but not in unstable angina [27]. Elevations are com-
mon in many non-cardiac diseases as well, e.g., stroke, sepsis,
respiratory tract infections, or gastroesofageal reflux [26, 28].
Given its rapid increase in acute illnesses, copeptin has
gained much interest as a tool for early ruling-out of MI [26,
27]. However, copeptin levels are also associated with LV
dysfunction and remodeling, in a similar fashion as the NPs
[29]. Accordingly, copeptin has been shown to be a strong
predictor of mortality and HF in patients with ACS [29–31,
32••]. One of the first analyses evaluating the prognostic value
of copeptin comes from the LAMP study enrolling 980 ACS
patients, the majority having STEMI [30]. Copeptin levels
independently predicted the combined endpoint of death or
hospitalization for HF at 1 year (OR 2.33 [95% CI 1.55–
3.49]), similarly as and additive to NT-proBNP. This indicates
that the stimuli of the secretion of these biomarkers are differ-
ent although both of them indicate hemodynamic stress.
Similar as NT-proBNP, copeptin did not predict recurrent is-
chemic events in this analysis. Among 224 patients with acute
MI and clinical HF from the OPTIMAAL study, higher
copeptin levels outperformed BNP and NT-proBNP in
predictingmajor cardiovascular (CV) events during 33months
of follow-up with a hazard ratio (HR) of 1.35 (95% confidence
interval [CI] 1.05–1.72) [31].
While these studies did not consider cTn levels, more ro-
bust data come from theMERLIN-TIMI 36 trial [32••]. In this
study, copeptin predicted the primary endpoint of CV death or
HF at 1 year, independent of clinical factors, NT-proBNP, and
cTnI measured with a sensitive assay (odds ratio [OR] 1.71
[95% CI 1.36–2.17]). Emerging data from studies in chest
pain patients, however, indicate that the added prognostic val-
ue of copeptin to cTn levels may be upheld when these are
measured with a hs-assay [33].
Biomarkers of Inflammation
CRP
C-reactive protein (CRP) is a phylogenetically highly
conserved plasma protein and is part of the systemic
response to inflammation [34]. CRP is an established
marker for the detection of (bacterial) infections and var-
ious inflammatory and necrotic processes. CRP has been
extensively studied as a marker for risk assessment in
ACS in the last 20 years [35]. In patients with MI,
CRP levels increase within 6 h after symptom onset
and peak 2–4 days later [36]. CRP increases in response
to myocardial injury and the maximum level is correlated
to the size of the MI [37]. CRP has been detected in
atherosclerotic plaques, but a causal relationship between
CRP and coronary events is highly unlikely [38].
In most studies looking at the prognostic value of
CRP in patients with NSTE-ACS, blood samples have
been obtained on admission or at inclusion into random-
ized clinical trials. The first small study indicating that
elevated CRP levels were associated with short-term CV
events in NSTE-ACS patients was published 1994 [39],
and thereafter, many studies have confirmed this associ-
ation extending it to long-term follow-up [35]. The prog-
nostic value of CRP regarding mortality is strong; the
data regarding future MI are less convincing [40•]. In a
meta-analysis based on 13 studies with 9787 patients and
a total of 1364 adverse events (mainly death or a com-
bination of death and MI), the pooled relative risks of
long-term adverse outcomes were 1.40 (95% CI 1.18–
1.67) for patients with CRP 3.1–10.0 mg/l and 2.18
(95% CI 1.77–2.68) for CRP >10.0 mg/l as compared
to CRP ≤3.0 mg/l [35].
However, whether measurement of CRP contributes
clinically relevant incremental information over and
above clinical risk scores and other biomarkers is still
controversial, and studies have shown contradictory re-
sults [15••, 41–44]. Notably, so far, no large study has
been done including hs-cTn assays. Furthermore, there
is no proven role for CRP for choice of treatment in
ACS [45].
ST2
ST2, a soluble interleukin‐1 receptor family member, is
upregulated and secreted in response to mechanical stress
[46]. It has been suggested that ST2 also is a marker of
inflammation, fibrosis, and adverse myocardial remodel-
ing [47, 48]. ST2 is only weakly correlated with other
biomarkers, such as cTn and the NPs, indicating different
modes of stimulation and release [49]. Hence, ST2 has
been extensively studied in patients with HF and has
been found to be strongly and independently associated
with mortality [47]. The FDA has approved an assay for
measurement of ST2 for prognostication in HF.
ST2 has been less extensively studied in ACS patients.
ST2 has clearly no role for the diagnosis of MI [50].
However, it has consistently shown independent prognos-
tic value both in studies in STEMI and NSTE-ACS re-
garding mortality or mortality/HF with HRs between 1.3
and 2.6 [49]. Unlike most other biomarkers, the prognos-
tic value of ST2 is more frequently studied in STEMI than
NSTE-ACS, and the HRs seem generally a little higher in
studies of STEMI than NSTE-ACS. In some [51], but not
all studies [32••, 52, 53], ST2 provided independent prog-
nostic value also when other biomarkers such as cTn or
NT-proBNP were entered in the multivariable models. In
a recent study of over 1200 patients with STEMI, a bio-
marker combination consisting of ST2, cTnT, and
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myeloperoxidase provided incremental prognostic infor-
mation to the TIMI STEMI risk score for the prediction
of short-term risk of CV death or HF [54•]. Whether ST2
is useful for the selection of treatment in ACS is un-
known. However, there is one study indicating that an
elevated ST2 level identifies patients with MI that benefit
from treatment with a mineralocorticoid receptor antago-
nist [55].
Growth Differentiation Factor-15—GDF-15
GDF-15 is a member of the transforming growth factor
β superfamily and is expressed in virtually all tissues,
suggesting important general cellular functions, although
its exact biological functions are still poorly understood
[56]. GDF-15 is involved in regulating inflammatory and
apoptotic pathways and is upregulated in many different
pathological conditions including, but not restricted to,
CV diseases [56].
GDF-15 levels have consistently been shown to be
strong and independent predictors of mortality and dis-
ease progression in patients with ACS. A meta-analysis
including 8903 patients from eight ACS studies found a
pooled HR of 1.66 (95% CI 1.47–1.87) regarding the
combined endpoint of death or MI [57]. In this analysis,
GDF-15 >1200 ng/L indicated a low risk and GDF-15
>1800 ng/L indicated a high risk for future CV events.
In the large PLATO trial evaluating 16,876 ACS pa-
tients followed for 1 year, higher levels of GDF-15 at
study inclusion were associated with raised risks of mor-
tality (HR 1.41 [95% CI 1.31–1.53]), spontaneous MI
(HR 1.15 [95% CI 1.05–1.26]), and stroke (HR 1.19
[95% CI 1.01–1.42]) as well as of all types of major
non-CABG-related bleeding (HR 1.37 [95% CI 1.25–
1.51]) [58••]. These risk estimates were independent of
clinical factors and levels of hs-cTnT, cystatin C, CRP,
and NT-proBNP. Similar findings emerged from a
subanalysis of the PROVE IT-TIMI 22 study investigat-
ing 3501 ACS patients followed for 2 years. In that
analysis, GDF-15 levels measured at hospital discharge
were significantly associated with the risk for death or
MI independent of clinical factors, BNP, and CRP [59].
In another study in NSTE-ACS patients, GDF-15 togeth-
er with NT-proBNP provided the strongest increment to
the GRACE risk score [18••].
In the FRISC-II trial randomizing patients with NSTE-
ACS to an invasive or conservative strategy with a follow-
up for 2 years, elevated GDF-15 levels independently pre-
dicted the risk of death or MI in the conservative group but
not in the invasive group. The interaction between GDF-15
levels and the treatment strategy was statistically significant
in this study [60]. These results indicate that GDF-15 might
be useful for the selection of patients for invasive treatment.
Somewhat in contrast to the lack of prognostic value of
GDF-15 in invasively treated patients in FRISC-II, the addi-
tion of levels of GDF-15, NT-proBNP and the extent of
coronary artery disease to clinical variables in a study of
5174 revascularized patients with NSTE-ACS from the
PLATO trial independently improved prognostication of
CV death or spontaneous MI (c-statistics 0.69 for the full
model vs 0.65 for the clinical model) [61].
Biomarkers of Renal Function
Estimated Glomerular Filtration Rate
ACS patients with chronic kidney disease (CKD) represent a
particularly vulnerable group. The correct estimation of renal
function is crucial for risk prediction in these patients, for
decision on treatment strategies and guidance of pharmaco-
logical dosing. However, the glomerular filtration cannot be
measured directly. In daily practice, the serum creatinine con-
centration or creatinine-based equations are used as surro-
gates. Serum creatinine is unfortunately an unreliable estimate
as it is insensitive for the detection of moderate reductions in
renal function and affected by factors such as age, gender,
muscle mass, physical activity, and diet.
The most commonly used equations to calculate the esti-
mated glomerular filtration rate (eGFR) are the Modification
of Diet in Renal Disease (MDRD) study formula and the
Cockcroft-Gault (CG) formula [62, 63]. There is a continued
debate on which of them is most accurate. None was devel-
oped or validated in patients with cardiac disease. In addition,
they differ in variables and coefficients. This results in lower
eGFR calculated by the CG formula in the elderly and subjects
with lower body mass index, cohorts known to be at higher
risk during and after ACS [64, 65]. Accordingly, the CG for-
mula has been shown to be superior for risk prediction com-
pared to the MDRD formula as it classifies more patients
subsequently having worse outcome to a lower renal function
stage [64, 65]. Recently, the Chronic Kidney Disease-
Epidemiology equation has been introduced as a more exact
estimate of the eGFR compared to the other formulas [66].
Results from the PLATO trial suggest that it also more closely
mirrors the risk of adverse events in ACS [67••].
Regardless of the applied equation, ACS patients have a
continuous increase in mortality risk along with decreasing
eGFR [15••, 64, 65, 67••, 68]. The association with recurrent
ischemic events is weaker and often abrogated following ad-
justment for clinical factors. Notably, most of these studies are
based on clinical trials in which patients with severe CKD or
dialysis had been excluded.
Only few studies have investigated the added prognos-
tic value of the eGFR to cTn levels [15••, 67••, 68]. This
likely reflects the fact that renal function assessment is
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an integral part of the management of patients with ACS.
While these studies demonstrated an added prognostic
value of the eGFR to cTn, the magnitude of this effect
seems only to be moderate [67••].
The prognostic interrelation between cTn and the
eGFR is complicated by the fact that small cTn eleva-
tions are common in subjects with severe CKD. This has
been attributed to myocardial wall stretch secondary to
volume overload, chronic myocardial ischemia, and
cardiotoxicity due to changes in osmolarity or ion fluxes
[69, 70]. Impaired renal clearance of immunoreactive
cTn fragments also contributes to cTn elevation, in par-
ticular in patients with more advanced CKD stages [71].
These prognostically less adverse mechanisms together
with a higher prevalence of other adverse comorbidities
contribute to a nonlinear relationship in the relative risk
associated with cTn levels along with decreasing eGFR:
despite higher absolute event rates and higher cTn levels
in more severe CKD, the relative risk estimates for cTn
tend to be lower compared to mild or moderate CKD
stages [72].
Cystatin C
The concerns regarding the various eGFR equations have
directed investigators to search for other, more reliable
markers of renal function. One of them is cystatin C, a
13-kDa protein that is constantly produced in all nucleat-
ed cells and filtered by the renal glomeruli without secre-
tion or subsequent reabsorption to the blood flow [73].
Cystatin C is considered to be more sensitive than serum
creatinine and at least as sensitive as eGFR equations for
the estimation of renal dysfunction [74]. Additional inter-
est in cystatin C arises from the fact that it is an inhibitor
of cytokine-activated elastolytic cysteine proteases that
are involved in the promotion of atherosclerotic plaques
and their destabilization [75]. Accordingly, cystatin C ap-
pears to reflect different pathways in ACS which hypo-
thetically might augment its prognostic value compared to
other estimates of renal function.
Cystatin C has been shown to be an independent
predictor of mortality in ACS. In some but not all stud-
ies, cystatin C was a stronger predictor of adverse out-
come than serum creatinine or the eGFR [76–78]. In the
so far largest study, a subanalysis from the PLATO trial
(16,401 ACS patients), the c-statistics of cystatin C re-
garding the combined endpoint of CV death or MI at
1 year was 0.69, similar as for the MDRD and CG
equations (C-statistics 0.69 for both). However, there
was no incremental prognostic value of cystatin C when
added to a clinical model including cTnI, hs-CRP, and
NT-proBNP [67••].
Summary and Outlook
There is an intense search for CV biomarkers that might add to
the prognostic information obtained from cTn levels, and
many of these biomarkers have been suggested for clinical
use. However, there are sti l l gaps in knowledge.
Surprisingly, few studies investigated such biomarkers in the
context of cTn results obtained with hs-assays. This leaves the
question whether positive results, in particular from older
studies hold true in contemporary settings where hs-cTn as-
says are increasingly used. Although many of the biomarkers
described in this mini-review may complement existing
methods for outcome prediction in ACS patients, there are
only few head-to-head comparisons. This kind of studies is
important for clinicians to appreciate the prognostic value of
any individual biomarker in a broader context. Results from
the PLATO and MERLIN-TIMI 36 studies suggest that bio-
markers of inflammation and renal function only provide
modest predictive value when clinical factors and cTn results
are taken into consideration. The NPs and GDF-15 are much
stronger risk indicators [22, 32••, 44, 67••] and have also been
shown to add considerable prognostic increment to the
GRACE score [18••]. Table 1 presents an overview regarding
the clinical utility of the biomarkers summarized in this mini-
review.
However, even a strong association with outcome is
seldom enough for a biomarker to be clinically useful. A
biomarker should also provide clinical information of
such magnitude that it directly affects the clinical man-
agement of each individual patient. Accordingly, studies
consistently supporting the benefit of specific therapeutic
interventions to modify the risk associated with higher
biomarker levels are needed to better define the utility
of such a biomarker. Such studies should also investigate
Table 1 Prognostic biomarkers in acute coronary syndrome
Biomarker Prognosis Selection of therapy
Death MI Heart failure
cTn +++ ++ ++ ++
BNP/NT-proBNP +++ - +++ +
Copeptin ++ - ++ -
CRP ++ - - -
ST2 ++ - ++ -
GDF-15 +++ + + +
eGFR ++ - + -
Cystatin C ++ - + -
MI myocardial infarction, cTn cardiac troponin, BNP B-type natriuretic
peptide, NT-proBNP N-terminal pro B-type natriuretic peptide, CRP C-
reactive protein,GDF-15 growth differentiation factor-15, eGFR estimat-
ed glomerular filtration rate
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whether a reduction in risk goes hand in hand with a
reduction in biomarker levels.
Even though data on numerous candidate biomarkers have
been published in the literature, they have a long way to go
before their clinical routine use can be recommended. This
leads to the question whether other approaches for improve-
ment of outcome prediction, not necessarily focusing on sin-
gle biomarkers, might be more useful. There has been a rapid
development of technologies for proteomic studies observing
1000–5000 proteins [79]. In analogy with genome-wide asso-
ciation studies, hypothesis-free association studies are under-
way to identify single biomarkers or biomarker clusters being
representative of distinct pathways in ACS [79, 80]. The as-
sessment of microRNAs is another option that has gained
increasing interest. MicroRNAs are small non-coding RNAs
that are key regulators of complex biological processes in-
volved in the development of various CV conditions.
Accumulating evidence suggests a potential role for
microRNAs as diagnostic tools in ACS and possibly, as prog-
nostic indicators [81]. A different, more clinically oriented
approach to maximize the wealth of prognostic information
obtained from biomarker results relies on their integration into
more complex predictive models [82, 83]. This overcomes the
limitations inherent to any single biomarker and such ap-
proaches are increasingly used in CV medicine.
Conclusion
Although the proliferation of new prognostic biomarkers in
ACS has been remarkable in recent years, only few of them
have convincingly proven incremental value to cTn results.
While the NPs and GDF-15 are most promising in this re-
gard, their role in clinical decision-making has yet to be
defined, in particular, with respect to biomarker-guided treat-
ment decisions in contemporary settings where hs-cTn as-
says are used.
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